News & Updates

Circulating homocysteine and folate concentrations appear to play a significant role in the development of nonalcoholic fatty liver disease (NAFLD), a study has shown.

YLB113, a biosimilar of the reference product etanercept, appears to be safe for long-term treatment of patients with rheumatoid arthritis, with efficacy sustained for up to 96 weeks, according to a study. Notably, the biosimilar is associated with fewer cases of injection-site reactions and injection-site erythema compared with the reference.

Ritlecitinib and brepocitinib as induction therapies for ulcerative colitis (UC) appear to be more effective than placebo while having an acceptable short-term safety profile, according to the results of a phase IIb study.

Women with a history of gestational diabetes mellitus (GDM) may benefit from habitual consumption of caffeinated coffee to prevent progression to type 2 diabetes (T2D) and have a more favourable metabolic profile, suggests a study.

The neutralizing antibody regdanvimab appears to be useful in the treatment of mild-to-moderate COVID-19, with a recent study showing that the drug may prevent disease worsening in patients, including those infected with the Delta variant.

The KRAS^G12C inhibitors, adagrasib and sotorasib, have shown promising antitumour activity in patients with heavily pretreated metastatic colorectal cancer (mCRC) and metastatic pancreatic cancer, respectively.